Physicians and patients weigh in on latest poorly designed study that raises the question, “Why?”, and, “Who is driving this spin?”

Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease

Comment

“Persister research needs to account for morphological variability of Lyme

The patient population studied was already a group that had shown persistence of disease. These would be “treatment failures” and more difficult cases. Even in this difficult population every group who received 2 weeks of IV ceftriaxone made an average 5 point improvement, and this 5 point improvement from their baseline essentially continued for a year after the conclusion of treatment, giving a new improved baseline. Ceftriaxone acts on the cell wall, whereas doxycycline and clarithromycin have intracellular activity…..”

Read full text

 

Leave a Reply

Your email address will not be published. Required fields are marked *